The Anti-HBV Drugs industry trends over the past 18 months reflect a surge in innovation and collaboration, driven by the urgent need for curative therapies. Key players have prioritized partnerships to accelerate R&D, such as Gilead Sciences’ alliance with Assembly Biosciences in 2023 to co-develop HBV cure candidates. Mergers & acquisitions have also intensified, with Merck’s strategic acquisition of a biotech firm specializing in RNA interference therapies for hepatitis B. Meanwhile, product/technology launches highlight advancements in oral nucleic acid polymer (NAP) therapies, including GlaxoSmithKline’s Phase III trials for GSK3228836, a first-in-class capsid inhibitor. Regulatory bodies, notably the FDA and EMA, have revised guidelines to expedite approvals for combination therapies targeting functional cures. On the consumer trend front, demand for non-invasive, shorter-duration treatment regimens has risen, pushing developers toward patient-centric drug designs. Finally, funding rounds totaling $250M in 2024 for startups like ReproVax underscore investor confidence in novel HBV vaccine platforms, signaling a shift toward preventive strategies in the market’s evolution.
